secwatch.observer — SEC 8-K summary
======================================

Issuer:     VivoSim Labs, INC. (VIVS)
CIK:        0001497253
Form:       8-K
Filed at:   2025-04-24T23:59:59+00:00
Accession:  0000950170-25-057685
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 5.03, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Organovo Holdings renames to VivoSim Labs, emerges from stealth to target FDA animal testing phase-out
--------------------------------------------------------------------------------

- Effective April 24, 2025, Organovo Holdings changed its name to VivoSim Labs, Inc. with new ticker symbol VIVS on Nasdaq.
- In conjunction with the name change, VivoSim issued a press release announcing emergence from stealth mode to provide NAM models for liver and intestinal toxicology.
- The FDA announced on April 10, 2025 a plan to phase out animal testing requirements, representing a potential >$10B market opportunity for VivoSim's non-animal technologies.
- VivoSim’s NAMkind liver model achieved industry-best correlation with known clinical failures, aiming to reduce clinical trial failures and cut drug development costs by 50%.
- The company's NAMkind intestine models offer novel readouts for drug candidate selection, targeting reduction of patient side effects from chemotherapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1497253/000095017025057685/0000950170-25-057685-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1497253/000095017025057685/vivs-20250423.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-057685

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer